Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 1
1997 1
1998 1
2006 3
2007 1
2008 3
2009 2
2010 3
2011 7
2012 13
2013 13
2014 25
2015 24
2016 17
2017 17
2018 25
2019 22
2020 23
2021 43
2022 28
2023 19
2024 21
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

282 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
BACKGROUND: Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple scle …
BACKGROUND: Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor …
Diagnosis and Treatment of Multiple Sclerosis: A Review.
McGinley MP, Goldschmidt CH, Rae-Grant AD. McGinley MP, et al. JAMA. 2021 Feb 23;325(8):765-779. doi: 10.1001/jama.2020.26858. JAMA. 2021. PMID: 33620411 Review.
These drugs include interferons, glatiramer acetate, teriflunomide, sphingosine 1-phosphate receptor modulators, fumarates, cladribine, and 3 types of monoclonal antibodies. ...Efficacy rates of current DMTs, defined by reduction in annualized relapse rates compared with p …
These drugs include interferons, glatiramer acetate, teriflunomide, sphingosine 1-phosphate receptor modulators, fumarates, cladribin …
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D'Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T. Kappos L, et al. JAMA Neurol. 2021 May 1;78(5):558-567. doi: 10.1001/jamaneurol.2021.0405. JAMA Neurol. 2021. PMID: 33779698 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients were randomized (1:1) to 20 mg of ponesimod or 14 mg of teriflunomide once daily and the placebo for 108 weeks, with a 14-day gradual up-titration of ponesimod starting at 2 mg to mitigate first-dose cardiac effects of S1P1 modulators and a f …
INTERVENTIONS: Patients were randomized (1:1) to 20 mg of ponesimod or 14 mg of teriflunomide once daily and the placebo for 108 week …
Pregnancy and multiple sclerosis: an update.
Varytė G, Arlauskienė A, Ramašauskaitė D. Varytė G, et al. Curr Opin Obstet Gynecol. 2021 Oct 1;33(5):378-383. doi: 10.1097/GCO.0000000000000731. Curr Opin Obstet Gynecol. 2021. PMID: 34310364 Free PMC article. Review.
Drugs with a known potential of teratogenicity such as fingolimod or teriflunomide should be avoided and recommended wash-out times for medications such as cladribine, alemtuzumab or ocrelizumab should be considered. Teriflunomide and fingolimod are not recommended …
Drugs with a known potential of teratogenicity such as fingolimod or teriflunomide should be avoided and recommended wash-out times f …
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
Gärtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, Deiva K, Ganjgahi H, Häring DA, Li B, Pingili R, Ramanathan K, Su W, Willi R, Kieseier B, Kappos L. Gärtner J, et al. Mult Scler. 2022 Sep;28(10):1562-1575. doi: 10.1177/13524585221078825. Epub 2022 Mar 10. Mult Scler. 2022. PMID: 35266417 Free PMC article. Clinical Trial.
BACKGROUND: In the phase III ASCLEPIOS I and II trials, participants with relapsing multiple sclerosis receiving ofatumumab had significantly better clinical and magnetic resonance imaging (MRI) outcomes than those receiving teriflunomide. OBJECTIVES: To assess the efficac …
BACKGROUND: In the phase III ASCLEPIOS I and II trials, participants with relapsing multiple sclerosis receiving ofatumumab had significantl …
Teriflunomide: Pediatric First Approval.
Paik J. Paik J. Paediatr Drugs. 2021 Nov;23(6):609-613. doi: 10.1007/s40272-021-00471-1. Paediatr Drugs. 2021. PMID: 34595696 Review.
On 18 June 2021, teriflunomide received its first approval in this indication in pediatric patients aged 10 years in the EU. This article summarizes the milestones in the development of teriflunomide leading to this first pediatric approval for relapsing-remitting M …
On 18 June 2021, teriflunomide received its first approval in this indication in pediatric patients aged 10 years in the EU. This art …
Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis.
Kang C, Blair HA. Kang C, et al. Drugs. 2022 Jan;82(1):55-62. doi: 10.1007/s40265-021-01650-7. Drugs. 2022. PMID: 34897575 Free PMC article. Review.
Ofatumumab had a generally manageable tolerability profile; the most common adverse events (AEs) included nasopharyngitis, headache, upper respiratory tract infections and urinary tract infections. ...In clinical trials, ofatumumab was more effective than teriflunomide …
Ofatumumab had a generally manageable tolerability profile; the most common adverse events (AEs) included nasopharyngitis, headache, …
Teriflunomide for multiple sclerosis.
He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L. He D, et al. Cochrane Database Syst Rev. 2016 Mar 22;3(3):CD009882. doi: 10.1002/14651858.CD009882.pub3. Cochrane Database Syst Rev. 2016. PMID: 27003123 Free PMC article. Review.
The quality of available data was too low to evaluate the benefit teriflunomide as monotherapy versus IFNbeta-1a or as combination therapy with IFNbeta. The common adverse effects were diarrhoea, nausea, hair thinning, elevated alanine aminotransferase, neutr …
The quality of available data was too low to evaluate the benefit teriflunomide as monotherapy versus IFNbeta-1a or as combination th …
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, Del Giovane C, Peryer G, Piggott T, Foschi M, Filippini G, Tramacere I, Baldin E, Nonino F. Gonzalez-Lorenzo M, et al. Cochrane Database Syst Rev. 2024 Jan 4;1(1):CD011381. doi: 10.1002/14651858.CD011381.pub3. Cochrane Database Syst Rev. 2024. PMID: 38174776 Free PMC article. Review.
Disability worsening over 36 months was assessed in three studies (2684 participants) but none of the studies used placebo as the comparator. Treatment discontinuation due to adverse events data were available from 43 studies (35,410 participants). Alemtuzumab probably res …
Disability worsening over 36 months was assessed in three studies (2684 participants) but none of the studies used placebo as the comparator …
Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.
Chan A, de Seze J, Comabella M. Chan A, et al. CNS Drugs. 2016 Jan;30(1):41-51. doi: 10.1007/s40263-015-0299-y. CNS Drugs. 2016. PMID: 26758290 Free PMC article. Review.
Across the clinical studies, teriflunomide was generally well tolerated; adverse events reported in 10% of teriflunomide-treated patients were diarrhea, nausea, increased alanine aminotransferase, and alopecia. Data from the clinical development program suppo …
Across the clinical studies, teriflunomide was generally well tolerated; adverse events reported in 10% of teriflunomide …
282 results